Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lobeline hydrochloride is a small molecule piperidine alkaloid derived from plants of the genus *Lobelia*, such as *Lobelia chinensis*. It acts as a nicotinic acetylcholine receptor (nAChR) agonist and mixed agonist-antagonist, specifically targeting the α3β2 and α4β2 neuronal subtypes. Beyond its cholinergic activity, lobeline hydrochloride functions as a ligand for the vesicular monoamine transporter 2 (VMAT2) and inhibits the reuptake of dopamine and serotonin. It also exhibits antagonist activity at μ-opioid receptors. Historically, the drug has been utilized as a respiratory stimulant in emergency medicine. It has also been extensively researched for its potential in smoking cessation and the treatment of addictions to substances such as cocaine, amphetamines, and alcohol. Shanghai Hefeng Pharmaceutical manufactures lobeline hydrochloride as a generic injectable product for first-aid and emergency use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lobeline hydrochloride.